1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Rhythm Biosciences Limited
  6. News
  7. Summary
    RHY   AU000000RHY2

RHYTHM BIOSCIENCES LIMITED

(RHY)
  Report
Delayed Australian Stock Exchange  -  05/24 08:20:25 pm EDT
1.175 AUD   -2.08%
05/12Rhythm Biosciences Files Listing for Colorectal Cancer Diagnostic Test
MT
05/03Rhythm Biosciences Closes Last Trial Site for Colorectal Cancer Study
MT
05/03Rhythm Biosciences Limited Closes Final Clinical Trial Site
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Rhythm Biosciences : Application for quotation of securities - RHY

12/02/2021 | 12:31am EDT

Application for quotation of +securities

Announcement Summary

For personal use only

Entity name

RHYTHM BIOSCIENCES LIMITED

Announcement Type

New announcement

Date of this announcement

Thursday December 02, 2021

The +securities to be quoted are:

+Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted

Total number of +securities to be quoted

ASX +security

Number of +securities to

code

Security description

be quoted

Issue date

RHY

ORDINARY FULLY PAID

1,768

02/12/2021

Refer to next page for full details of the announcement

Application for quotation of +securities

1 / 7

Application for quotation of +securities

Part 1 - Entity and announcement details

For personal use only

1.1 Name of entity

RHYTHM BIOSCIENCES LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2

Registered number type

Registration number

ABN

59619459335

1.3

ASX issuer code

RHY

  1. The announcement is New announcement
  2. Date of this announcement

2/12/2021

Application for quotation of +securities

2 / 7

Application for quotation of +securities

Part 2 - Type of Issue

For personal use only

2.1 The +securities to be quoted are:

+Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted

2.2 The +securities to be quoted are:

Additional +securities in a class that is already quoted on ASX ("existing class")

Application for quotation of +securities

3 / 7

Application for quotation of +securities

Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

only

Existing +securities converting into additional +securities in an existing class

FROM (Existing Class)

ASX +security code and description

RHYAK : OPTION EXPIRING 31-AUG-2022 EX $1.20

use

TO (Existing Class)

ASX +security code and description

RHY : ORDINARY FULLY PAID

Please state the number of options that were exercised or other +convertible securities that were converted

1,028

The first date the options were exercised or other +convertible securities were converted

2/12/2021

The last date the options were exercised or other +convertible securities were converted

2/12/2021

For personal

Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)?

No

The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by:

An issue of new +securities

The underlying securities being received by the holder are:

Intended to be, but are not yet, quoted by ASX

Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme?

No

Issue date

2/12/2021

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Application for quotation of +securities

4 / 7

Application for quotation of +securities

Issue details

Number of +securities to be quoted

1,028

use only

Are the +securities being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid? What is the issue price per +security?

AUD - Australian Dollar

AUD 1.20000000

Any other information the entity wishes to provide about the +securities to be quoted

Existing +securities converting into additional +securities in an existing class

FROM (Existing Class)

ASX +security code and description

RHYAL : OPTION EXPIRING 31-JUL-2024 $1.80

personal

TO (Existing Class)

ASX +security code and description

RHY : ORDINARY FULLY PAID

Please state the number of options that were exercised or other +convertible securities that were converted

740

The first date the options were exercised or other +convertible securities were converted

2/12/2021

The last date the options were exercised or other +convertible securities were converted

2/12/2021

For

Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)?

No

The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by:

An issue of new +securities

The underlying securities being received by the holder are:

Intended to be, but are not yet, quoted by ASX

Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme?

No

Application for quotation of +securities

5 / 7

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Rhythm Biosciences Ltd. published this content on 02 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 December 2021 05:30:07 UTC.


© Publicnow 2021
All news about RHYTHM BIOSCIENCES LIMITED
05/12Rhythm Biosciences Files Listing for Colorectal Cancer Diagnostic Test
MT
05/03Rhythm Biosciences Closes Last Trial Site for Colorectal Cancer Study
MT
05/03Rhythm Biosciences Limited Closes Final Clinical Trial Site
CI
04/26RHYTHM BIOSCIENCES : Application for quotation of securities - RHY
PU
04/11RHYTHM BIOSCIENCES : Application for quotation of securities - RHY
PU
04/06RHYTHM BIOSCIENCES : Application for quotation of securities - RHY
PU
04/05RHYTHM BIOSCIENCES : RHY Presentation at PAC Partners Healthcare Conference
PU
04/04RHYTHM BIOSCIENCES : Investor Presentation
PU
04/04Rhythm Biosciences Meets Primary Endpoint in Accuracy Trial for Cancer Diagnostic Kit; ..
MT
04/03Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (S..
CI
More news
Financials
Sales 2021 1,11 M 0,78 M 0,78 M
Net income 2021 -6,61 M -4,67 M -4,67 M
Net cash 2021 2,27 M 1,61 M 1,61 M
P/E ratio 2021 -24,8x
Yield 2021 -
Capitalization 257 M 182 M 182 M
EV / Sales 2020 61,6x
EV / Sales 2021 159x
Nbr of Employees -
Free-Float 55,4%
Chart RHYTHM BIOSCIENCES LIMITED
Duration : Period :
Rhythm Biosciences Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHYTHM BIOSCIENCES LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Glenn Gilbert Managing Director & Director
Otto Leslie Steven Buttula Executive Chairman
Trevor John Lockett Executive Director & Technical Director
Rachel David Independent Non-Executive Director
Louis James Panaccio Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RHYTHM BIOSCIENCES LIMITED-25.48%183
EXACT SCIENCES CORPORATION-33.19%9 149
BGI GENOMICS CO., LTD.-21.41%4 183
GUARDANT HEALTH, INC.-62.03%3 871
IOVANCE BIOTHERAPEUTICS, INC.-21.37%2 359
SEEGENE, INC.-30.98%1 774